PF-Atlas › Treatments › Nerandomilast / Jascayd
Nerandomilast / Jascayd
Selective PDE4B inhibitor — elevates cAMP, suppresses pro-inflammatory cytokines and fibroblast activation
Clinically established — FDA-approved or positive Phase III. How PF-Atlas grades evidence.
Development stage
FDA Approved Oct 2025
Evidence level
Level 1 (FDA Approved)
Mechanism class
Selective PDE4B inhibitor — elevates cAMP, suppresses pro-inflammatory cytokines and fibroblast activation
Timeline
Available Now
Risk profile
Low
Developer
Boehringer Ingelheim
Key researchers
G. Raghu
Overview
FDA approved Oct 2025 for IPF, Dec 2025 for PPF. First new IPF drug in a decade. FIBRONEER-IPF/ILD Phase III: significantly reduced FVC decline vs placebo, works with or without nintedanib/pirfenidone. Oral, once daily.
How Nerandomilast / Jascayd fits into IPF treatment
Nerandomilast / Jascayd is classified as Level 1 (FDA Approved) at the FDA Approved Oct 2025 stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Nerandomilast / Jascayd for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.